US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Bristol-Myers Squibb Company

BMYNYSE

74.52

USD
-0.01
(-0.01%)
Market Closed
25.26P/E
9Forward P/E
1.15P/E to S&P500
158.441BMarket CAP
2.94%Div Yield
Google Trends
Recent Reddit Comments
Nothing found
Recent Tweets
$BMY *ALL THESE LEVELS POSTED AHEAD OF TIME BEFORE THE MARKET OPENED.. https://t.co/AMj3zB4yrF
0
0
0
Speaking as a former pharma reporter, this is one interesting read, from @LinnaneCiara $BMY $PFE $AZN $SNY https://t.co/dYSgHFMlVz
0
0
0
In its final hour #tesla is more conventional & less imaginative #death tied to $BIIB & eisai #alzheimers #drug, #sciencereview $BMY breyanzi approved lbcl #therapy in japan $VALE PT ↑ $20 from $16 #therapisttwitter $KR #health, #prime agreement $HAL call volume #bullish https://t.co/yI5yfP2uP8
0
0
14
$BMY Awaiting Buy Signal based off 34 signals on the 15-min chart. Free trial at https://t.co/zfbFwkv9c2 https://t.co/4HskvXBTdG
0
0
0
$BMY not a barn burner of a name, but closing at new weekly high out of this two decade base. Daily could use some rest but maybe one to watch for the longer-term players out there. $MRK similar. https://t.co/xUns3807JL
0
0
0
Added 2 more shares of $BMY today
2
1
10
$MRK, $JNJ, $AMGN, $BMY lower lows on daily Even if they sold off by another 15-20%, they will still be expensive that’s how much bloated they are 🤷🏻‍♂️😂
3
1
7
Chasing beta is equivalent to $MRK, $BMY, $JNJ, $AMGN dump 🤷🏻‍♂️😜
0
0
2
$GILD $BMY - Bristol-Myers Squibb rebuffed again by Supreme Court on $1.2B Gilead patent dispute https://t.co/HXP5fIiHQv
0
0
2
$BMY- been consolidating in this 73.31 and 72.24 range. Ready to make a move. 200ema at 73.13, claim it and it goes. https://t.co/V4lDARIhA7
3
2
20
Now I know why WS sold off $pdsb after acquiring PDS0301. Look at these preclinical models of various combinations of the triplet study. Why would PDS want this POS? I ask sarcastically https://t.co/wvSzx1baoQ What happens WHEN we use $mrk Keytruda or $bmy Opdivo instead of BA? https://t.co/qLkAgpuuPz
5
3
14
Annualized Return Since 1957 🤯 🚬 $MO 18.02% 🥼 $ABT 15.76% 🧋 $PEP 14.02% 😷 $BMY 13.77% 🥤 $KO 13.75% 🚜 $DE 13.74% 🦷 $CL 13.62% 🍫 $HSY 13.60% 💉 $PFE 13.52% 🛒 $KR 13.40% 🩺 $MRK 13.36% 🏪 $CVS 13.27% 🛍️ $PG 13.00% 🥣 $GS 12.59% 🧻 $KMB 11.64% #DivTwit
1
17
56
Notable LOEs through 2028 (with at-risk revenue estimates) $BMY, $MRK, $JNJ and $ABBV among the most impacted With >$175B in cumulative sales at-risk & record amounts of cash on hand, the stage appears set for a rebound in M&A https://t.co/hc0D7tl6Ul
6
29
137
Top 10 drugs to watch heading into 2023 (for drugs first approved in 2022) Ranked by sell-side 2027 sales estimates, which may reflect more than 1 indication (i.e. Mounjaro reflects obesity + T2D) $LLY leads the way with Mounjaro, with $BMY second ($5.8B) based on 3 approvals https://t.co/gETzs0Slxm
3
23
74
$BMY goes ex-div 5JAN First dividend at $0.57 per quarter following the recently announced hike (+6%) current yield 3.2% https://t.co/QMBdobvKB1
1
1
31
Drugmakers including Pfizer, $PFE, GlaxoSmithKline PLC, $GSK, Bristol Myers Squibb, $BMY, AstraZeneca, $AZN and Sanofi plan to raise prices in the United States on more than 350 unique drugs in early January, per Reuters.
97
179
655
Author @DVI_Investing reviews 10 #stocks that he has either in his #portfolio now or in the process of building a position in them. Check out his list. $PG $V $BMY $MO $PEP $TROW $HD $RTX $CMCSA $MSFT #dividends #dividend #StocksToWatch #StocksInFocus https://t.co/DYkTxlPtgp
0
4
4